|
|
 Previous Article | Table of Contents | Next Article 
Erythropoietin-induced activation of STAT5 is impaired in the
myelodysplastic syndrome
LH Hoefsloot, MP van Amelsvoort, LC Broeders, DC van der Plas, K van Lom, H Hoogerbrugge, IP Touw and B Lowenberg
Institute of Hematology, Erasmus University Rotterdam, Department of
Hematology, Dijkzigt Hospital, Rotterdam, The Netherlands.
Patients with myelodysplastic syndrome (MDS) have ineffective in vivo and
in vitro erythropoiesis, characterized by an impaired response to
erythropoietin (Epo). We examined proliferation and maturation of MDS
marrow cells in response to Epo in more detail. Epo-dependent DNA synthesis
as well as induction of GATA-1 binding activity in marrow cells from 15 MDS
cases were severely reduced as compared with normal bone marrow (NBM).
Additionally, the appearance of morphologically identifiable erythroid
cells was decreased in MDS cell cultures. These data indicate that both the
Epo-dependent proliferation as well as the differentiation induction by Epo
is suppressed. To study more upstream events of the Epo signal transduction
route we investigated activation of the signal transducer and activator of
transcription (STAT) 5. In all 15 MDS samples tested, STAT5 activation was
absent or greatly suppressed in response to Epo. In contrast, interleukin-3
induced a normal STAT5 response in MDS cells. Further, in MDS the subset of
CD71+ BM cells that is phenotypically similar to Epo-responsive cells in
normal marrow, was present. We conclude that the Epo response in MDS is
disturbed at an early point in the Epo-receptor (EpoR) signal transduction
pathway.
Volume 89,
Issue 5,
pp. 1690-1700,
03/01/1997
Copyright © 1997 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
K. Shannon and L. R. Silverman
Myelodysplastic syndrome and overlap syndromes
ASH Self-Assessment Program,
January 1, 2007;
2007(1):
228 - 242.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. List, M. Estes, G. Gao, A. Janokowska, and J. Maciejewski
Large CD45 Protein Tyrosine Phosphatase (PTP) Isoforms Predominate in Myelodysplastic Erythroid Precursors and Attenuate the Erythropoietin (EPO): STAT5 Signal.
Blood (ASH Annual Meeting Abstracts),
November 16, 2006;
108(11):
2650 - 2650.
[Abstract]
[PDF]
|
|
|
|
|
|
|
U. Schmidt, E. van den Akker, M. Parren-van Amelsvoort, G. Litos, M. de Bruijn, L. Gutierrez, R. W. Hendriks, W. Ellmeier, B. Lowenberg, H. Beug, et al.
Btk Is Required for an Efficient Response to Erythropoietin and for SCF-controlled Protection against TRAIL in Erythroid Progenitors
J. Exp. Med.,
March 15, 2004;
199(6):
785 - 795.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. M. Fuhler, A. L. Drayer, and E. Vellenga
Decreased phosphorylation of protein kinase B and extracellular signal-regulated kinase in neutrophils from patients with myelodysplasia
Blood,
February 1, 2003;
101(3):
1172 - 1180.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. L. Darley, L. Pearn, N. Omidvar, M. Sweeney, J. Fisher, S. Phillips, T. Hoy, and A. K. Burnett
Protein kinase C mediates mutant N-Ras-induced developmental abnormalities in normal human erythroid cells
Blood,
December 1, 2002;
100(12):
4185 - 4192.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. R. Silverman, E. P. Demakos, B. L. Peterson, A. B. Kornblith, J. C. Holland, R. Odchimar-Reissig, R. M. Stone, D. Nelson, B. L. Powell, C. M. DeCastro, et al.
Randomized Controlled Trial of Azacitidine in Patients With the Myelodysplastic Syndrome: A Study of the Cancer and Leukemia Group B
J. Clin. Oncol.,
May 15, 2002;
20(10):
2429 - 2440.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. F. List
New Approaches to the Treatment of Myelodysplasia
Oncologist,
April 1, 2002;
7(90001):
39 - 49.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
U. Bunworasate, H. Arnouk, H. Minderman, K. L. O'Loughlin, S. N. J. Sait, M. Barcos, C. C. Stewart, and M. R. Baer
Erythropoietin-dependent transformation of myelodysplastic syndrome to acute monoblastic leukemia
Blood,
December 1, 2001;
98(12):
3492 - 3494.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. T. Bellamy, L. Richter, D. Sirjani, C. Roxas, B. Glinsmann-Gibson, Y. Frutiger, T. M. Grogan, and A. F. List
Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes
Blood,
March 1, 2001;
97(5):
1427 - 1434.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Hellstrom-Lindberg, C. Willman, A. J. Barrett, and Y. Saunthararajah
Achievements in Understanding and Treatment of Myelodysplastic Syndromes
Hematology,
January 1, 2000;
2000(1):
110 - 132.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. C. Ward, I. Touw, and A. Yoshimura
The Jak-Stat pathway in normal and perturbed hematopoiesis
Blood,
January 1, 2000;
95(1):
19 - 29.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. L. Heaney and D. W. Golde
Myelodysplasia
N. Engl. J. Med.,
May 27, 1999;
340(21):
1649 - 1660.
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Okajima, I. Matsumura, T. Nishiura, K. Hashimoto, H. Yoshida, J. Ishikawa, H. Wakao, A. Yoshimura, Y. Kanakura, Y. Tomiyama, et al.
Insulin-like Growth Factor-I Augments Erythropoietin-induced Proliferation through Enhanced Tyrosine Phosphorylation of STAT5
J. Biol. Chem.,
September 4, 1998;
273(36):
22877 - 22883.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. von Lindern, M. P.-v. Amelsvoort, T. van Dijk, E. Deiner, E. van den Akker, S. van Emst-de Vries, P. Willems, H. Beug, and B. Lowenberg
Protein Kinase C alpha Controls Erythropoietin Receptor Signaling
J. Biol. Chem.,
October 27, 2000;
275(44):
34719 - 34727.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
